HAE vs TFX

For growth investors, Haemonetics Corporation (HAE) is the stronger pick with 4.

0% revenue growth year-over-year, versus -34. 6% for Teleflex Incorporated (TFX). Haemonetics Corporation (HAE) offers the better valuation at 15. 9x trailing P/E (10. 6x forward), making it the more compelling value choice. Analysts rate Haemonetics Corporation (HAE) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Haemonetics Corporation is actually cheaper at 10.

6x.

Over the past 5 years, Haemonetics Corporation (HAE) delivered a total return of -14.

3%, compared to -68. 1% for Teleflex Incorporated (TFX). Over 10 years, the gap is even starker: HAE returned +89. 4% versus TFX's -15. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Haemonetics Corporation (HAE) is the lower-risk stock at 0.

48β versus Teleflex Incorporated's 1. 06β — meaning TFX is approximately 122% more volatile than HAE relative to the S&P 500. On balance sheet safety, Teleflex Incorporated (TFX) carries a lower debt/equity ratio of 87% versus 149% for Haemonetics Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Haemonetics Corporation (HAE) is pulling ahead at 4.

0% versus -34. 6% for Teleflex Incorporated (TFX). On earnings-per-share growth, the picture is similar: Haemonetics Corporation grew EPS 44. 5% year-over-year, compared to -1468. 2% for Teleflex Incorporated. Over a 3-year CAGR, HAE leads at 11. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Haemonetics Corporation (HAE) is the more profitable company, earning 12.

3% net margin versus -45. 4% for Teleflex Incorporated — meaning it keeps 12. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HAE leads at 16. 3% versus 12. 8% for TFX. At the gross margin level — before operating expenses — HAE leads at 57. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Haemonetics Corporation (HAE) trades at 10.

6x forward P/E versus 18. 3x for Teleflex Incorporated — 7. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HAE: 60. 7% to $84. 60.

In this comparison, TFX (1.

1% yield) pays a dividend. HAE does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Haemonetics Corporation (HAE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

48)). Both have compounded well over 10 years (HAE: +89. 4%, TFX: -15. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HAE is a small-cap deep-value stock; TFX is a small-cap quality compounder stock. TFX pays a dividend while HAE does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.